Trade Sage Therapeutics, Inc. - SAGE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 4.82 |
| Open | 4.87 |
| 1-Year Change | -74.82% |
| Day's Range | 4.87 - 5.11 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 21, 2024 | 4.82 | -0.12 | -2.43% | 4.94 | 5.12 | 4.77 |
| Nov 20, 2024 | 4.89 | 0.19 | 4.04% | 4.70 | 5.10 | 4.55 |
| Nov 19, 2024 | 4.90 | 0.23 | 4.93% | 4.67 | 4.92 | 4.65 |
| Nov 18, 2024 | 4.76 | -0.25 | -4.99% | 5.01 | 5.01 | 4.71 |
| Nov 15, 2024 | 5.06 | -0.28 | -5.24% | 5.34 | 5.34 | 5.01 |
| Nov 14, 2024 | 5.34 | -0.27 | -4.81% | 5.61 | 5.61 | 5.31 |
| Nov 13, 2024 | 5.69 | 0.04 | 0.71% | 5.65 | 5.83 | 5.55 |
| Nov 12, 2024 | 5.72 | -0.46 | -7.44% | 6.18 | 6.25 | 5.68 |
| Nov 11, 2024 | 6.27 | -0.14 | -2.18% | 6.41 | 6.62 | 6.25 |
| Nov 8, 2024 | 6.29 | 0.03 | 0.48% | 6.26 | 6.34 | 6.13 |
| Nov 7, 2024 | 6.29 | 0.38 | 6.43% | 5.91 | 6.39 | 5.81 |
| Nov 6, 2024 | 5.92 | -0.40 | -6.33% | 6.32 | 6.37 | 5.88 |
| Nov 5, 2024 | 5.90 | 0.25 | 4.42% | 5.65 | 5.91 | 5.60 |
| Nov 4, 2024 | 5.79 | -0.05 | -0.86% | 5.84 | 6.09 | 5.78 |
| Nov 1, 2024 | 6.03 | -0.06 | -0.99% | 6.09 | 6.12 | 5.80 |
| Oct 31, 2024 | 6.04 | -0.28 | -4.43% | 6.32 | 6.48 | 5.88 |
| Oct 30, 2024 | 6.40 | -1.41 | -18.05% | 7.81 | 7.89 | 6.15 |
| Oct 29, 2024 | 8.46 | 0.07 | 0.83% | 8.39 | 8.65 | 8.32 |
| Oct 28, 2024 | 8.50 | 0.52 | 6.52% | 7.98 | 8.58 | 7.98 |
| Oct 25, 2024 | 7.99 | 0.16 | 2.04% | 7.83 | 8.12 | 7.80 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Sage Therapeutic Company profile
About SAGE Therapeutics Inc
SAGE Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing medicines with debilitating disorders of the brain. The Company's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD), in adults. The Company's products also include ZULRESSO (Brexanolone) CIV Injection, Zuranolone (SAGE-217), SAGE-324 and SAGE-718. Its next advanced product candidate is SAGE-217, is an oral compound that is in Phase III clinical development in PPD and depressive disorder (MDD). Zuranolone is a neuroactive steroid that, like brexanolone, is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. SAGE-324 is a GABAA receptor positive allosteric modulator intended for chronic oral dosing and conducting a placebo-controlled Phase II clinical trial evaluating the safety and efficacy of SAGE-324 in the treatment of essential tremor.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, SAGE Therapeutics Inc revenues decreased 99% to $6.3M. Net loss totaled $457.9M vs. income of $606.1M. Revenues reflect Collaboration revenue decrease from $1.11B to $0K, Product decrease of 6% to $6.3M. Net loss reflects Stock-based Compensation in R&D increase of 17% to $49.7M (expense), Stock-based Compensation in SGA increase of 6% to $54.9M (expense), Other income (expense).
Equity composition
Common Stock, $0.0001 Par, 07/14, auth. 120M shares,. 24,961,926 issd,. Insiders owns approx. 20.03%.
| Industry: | Bio Therapeutic Drugs |
215 1st St
CAMBRIDGE
MASSACHUSETTS 02142
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com